Olympus 2008 Annual Report Download - page 10

Download and view the complete annual report

Please find page 10 of the 2008 Olympus annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 68

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68

By doing so, ITX Corporation has consolidated its
core business bases and renewed its investment
portfolio based on a review of its investment
securities ownership policy. ITX Corporation plans
to optimize its portfolio in fiscal 2009. By making
steady contributions to consolidated business
earnings, ITX Corporation will serve as a catalyst in
the creation of new Olympus Group businesses.
Aiming for Sustainable Growth
> In fiscal 2009, Olympus forecasts net sales of
¥1,150 billion and record-high sales for the 15th
consecutive year. On the earnings front, however,
we anticipate operating income of ¥95 billion due
to the impact of the strong yen. Establishing solid
profitability that will be immune to such factors as
foreign currency exchange fluctuations will neces-
sitate streamlining the entire business process
and developing new businesses.
Olympus will make every effort to maximize its
corporate value and meet the expectations of all
of its stakeholders, including shareholders. We
sincerely ask for continued understanding and
support.
July 2008
Tsuyoshi Kikukawa
President
In the micro-imaging field, studies into the
cancer metastasis mechanism, drug efficacy
and metabolism are making progress, following
the realization of intracellular gene observation.
Thanks to the laser microscope, which has enabled
observation of the innermost recesses of nerve
cells for the first time, great strides are also being
made in studies in the field of brain neuroscience.
This study research can open the door to next-
generation medicine and business opportunities
there. There is high demand for industrial micro-
scopes that serve as measurement devices for
semiconductors and other leading-edge materials.
Consequently, we are making ongoing efforts to
expand our market by leveraging our high-precision
optical technologies.
In the diagnostic systems field, Olympus has
made a full-scale entry into the immunoassay
business to complement its existing clinical
chemistry examination business. To that end, we
will fully utilize our genetic and protein analysis
technologies to develop a genetic diagnostic
systems business that will make a valuable con-
tribution to personalized medicine. Furthermore,
the biomedical materials business conducted by
Olympus Terumo Biomaterials Corp., a joint venture
established with Terumo Corporation, is expected
to become a mainstay business in the regenerative
medicine area.
ITX Corporation:
Catalyst for New Business Creation
> Since fiscal 2008, consolidated subsidiary ITX
Corporation has engaged in structural reforms
to strengthen its earnings capabilities. One of
the key measures taken under these reforms has
been to concentrate investment in its three core
businesses—mobile handset sales, automotive
aftermarket and medical systems, as well as their
related markets—to enhance profitability.
8 OLYMPUS 2008